StockData

Mirum Pharmaceuticals vs Pacira BioSciences

MIRM and PCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MIRM and PCRX compare

Mirum Pharmaceuticals is the larger company, worth 4.1 times as much as Pacira BioSciences ($6.0B against $1.5B).

Mirum Pharmaceuticals grew revenue faster over the last twelve months (44.0% versus 5.7% for Pacira BioSciences).

Pacira BioSciences keeps more of each dollar of sales as profit, with a net margin of 2.0% compared with −139% at Mirum Pharmaceuticals.

Pacira BioSciences scores higher on the StockData Score (6 against 5 for Mirum Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMIRMPCRX
Size and price
Market cap$6.0B$1.5B
Share price$91.95$36.48
Change, 1 year28.7%53.4%
Change, 5 years586%−29.3%
Beta (5Y)0.610.12
Employees372829
StockData Score
Total score56 (better)
Valuation score00
Growth score3 (better)1
Performance score13 (better)
Health score12 (better)
Dividend score00
Valuation
P/E–104×
P/S9.7×1.9× (better)
P/B–2.2×
EV/EBITDA–14.9×
P/FCF–8.1×
FCF yield−3.8%12.3% (better)
Fair value–$28.47
Margin of safety–−28.1%
Growth
Revenue growth (TTM)44.0% (better)5.7%
Revenue growth, 5Y average–11.1%
EPS growth, 5Y average–−45.5%
Profitability
Gross margin–79.2%
Operating margin−135%2.7% (better)
Net margin−139%2.0% (better)
FCF margin−37.0%24.1% (better)
Return on equity−703%2.0% (better)
Return on invested capital–3.0%
Financial health
Debt / equity–0.54
Net debt / EBITDA–1.07
Interest coverage−62.1×1.3× (better)
Current ratio2.865.04 (better)
Altman Z-score−0.222.44 (better)
Piotroski F-score58 (better)
Dividends and buybacks
Buyback yield–10.2%
Shareholder yield0.00%10.2% (better)
Ownership
Held by institutions110%110%
Held by insiders9.2%6.1%
Insider net buying, 12 months−$32.8M−$2.4M (better)
Short interest, % of float11.1%8.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.